Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | TACR3 | P29371 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | PTGFR | P43088 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668093 | 0.94 | LMNA (0.65) | LMNATP53TACR3CNR1RAB9A | |
| SCHEMBL4665602 | 0.87 | LMNA (0.57) | LMNATP53TACR3TACR2NAMPT | |
| SCHEMBL5140190 | 0.81 | LMNA (0.76) | LMNATP53TACR3PTGFRMAPT | |
| SCHEMBL4668145 | 0.81 | DHODH (0.60) | LMNATACR3TACR2 | |
| SCHEMBL4667070 | 0.81 | LMNA (0.74) | LMNATP53TACR3PTGFRMAPT | |
| SCHEMBL4665273 | 0.78 | LMNA (0.67) | LMNATP53TACR3PTGFRMAPT | |
| SCHEMBL4666988 | 0.78 | SMN1; SMN2 (0.51) | LMNATP53TACR3MAPTTACR2 | |
| SCHEMBL4667071 | 0.78 | LMNA (0.71) | LMNATP53TACR3PTGFRMAPT | |
| SCHEMBL5048810 | 0.78 | LMNA (0.71) | LMNATP53TACR3PTGFRMAPT | |
| SCHEMBL4984967 | 0.78 | LMNA (0.47) | LMNATP53TACR3PTGFRTACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891012-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006130080-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | claimed |
| EP-1891012-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130080-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |